Carbone, Maria Luigia
Madonna, Gabriele
Capone, Alessia
Bove, Marianna
Mastroeni, Simona
Levati, Lauretta
Capone, Mariaelena
Ascierto, Paolo Antonio
De Galitiis, Federica
D’Atri, Stefania
Fortes, Cristina
Volpe, Elisabetta
Failla, Cristina Maria
Funding for this research was provided by:
Fondazione Umberto Veronesi (Research fellowship)
Ministero della Salute (M2/2, RC4.1, 2018-2020)
Article History
Received: 13 August 2021
Accepted: 21 March 2022
First Online: 31 March 2022
Competing interests
: Paolo A. Ascierto has/had a consultant/advisory role for Bristol Myers Squibb, Roche-Genentech, Merck Sharp & Dohme, Novartis, Array, Merck Serono, Pierre-Fabre, Incyte, Medimmune, AstraZeneca, Syndax, Sun Pharma, Sanofi, Idera, Ultimovacs, Sandoz, Im-munocore, 4SC, Alk-ermes, Italfarmaco, Nektar, Boehringer-Ingelheim, Eisai, Regeneron, Daiichi Sankyo, Pfizer, Oncosec, Nouscom, Takis, Lunaphore. He also received research funding from Bristol Myers Squibb, Roche-Genentech, Array, Sanofi, and travel support from MSD. All outside the submitted work. All the other authors declare no competing interests.